Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Lisata Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +1 vs. Q4 2024
- Shares held
- 783.4K
- −2.37K (−0.3%) vs. Q4 2024
- Total value
- $1.84M
- −$492.9K (−21.1%) vs. Q4 2024
- New holders
- 3
- 6 more added
- Sold out
- 2
- 5 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LSTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $3.70M |
| Q1 2026 | 34 | $7.06M |
| Q4 2025 | 25 | $1.36M |
| Q3 2025 | 21 | $1.93M |
| Q2 2025 | 20 | $2.26M |
| Q1 2025 | 22 | $1.84M |
| Q4 2024 | 21 | $2.33M |
| Q3 2024 | 20 | $2.30M |
| Q2 2024 | 22 | $2.61M |
| Q1 2024 | 21 | $2.30M |
| Q4 2023 | 22 | $2.03M |
| Q3 2023 | 21 | $1.46M |
| Q2 2023 | 22 | $2.51M |
| Q1 2023 | 21 | $2.08M |
| Q4 2022 | 24 | $1.83M |
| Q3 2022 | 22 | $2.17M |
| Q2 2022 | 36 | $5.00M |
| Q1 2022 | 34 | $6.13M |
| Q4 2021 | 36 | $7.33M |
| Q3 2021 | 34 | $9.41M |
| Q2 2021 | 29 | $10.1M |
| Q1 2021 | 33 | $12.9M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Lisata Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 1 | $2 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1 | $2 | 0.00% | 00.0% | Unchanged |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 2 | $5 | 0.00% | +2 | New |
| Cheviot Value Management, LLC | 3 | $7 | 0.00% | +3 | New |
| Barclays PLC | 4 | $9 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 13 | $31 | 0.00% | −2−13.3% | Reduced |
| SBI Securities Co., Ltd. | 140 | $329 | 0.00% | −400−74.1% | Reduced |
| Morgan Stanley | 1,466 | $3.45K | 0.00% | 00.0% | Unchanged |
| Founders Capital Management | 2,000 | $4.70K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,207 | $5.19K | 0.00% | +292+15.2% | Added |
| Royal Bank of Canada | 5,912 | $14.0K | 0.00% | +5,860+11,269.2% | Added |
| HighTower Advisors, LLC | 10,042 | $23.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 10,268 | $24.1K | 0.00% | +10,268 | New |
| Bank of America Corp | 10,413 | $24.5K | 0.00% | +30.0% | Added |
| Cook Wealth Management Group LLC | 12,175 | $29.3K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 14,348 | $33.7K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 25,222 | $59.3K | 0.00% | −40.0% | Reduced |
| BlackRock, Inc. | 54,857 | $128.9K | 0.00% | −1,156−2.1% | Reduced |
| Geode Capital Management, LLC | 60,529 | $142.3K | 0.00% | +4,634+8.3% | Added |
| Renaissance Technologies LLC | 102,722 | $241.4K | 0.00% | +1,400+1.4% | Added |
| BML Capital Management, LLC | 216,853 | $509.6K | 0.41% | −67,816−23.8% | Reduced |
| Vanguard Group Inc | 254,182 | $597.3K | 0.00% | +67,816+36.4% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −23,273−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |